Abstract：Antibiotic resistance led to the clinical use of β-lactam antibiotics (BL) severely limited, whereas β-lactamase inhibitors (BLI) perfectly resolved this problem in combination with BL. In recent years, the novel antibiotic compounds have been developed rapidly in Europe and the United states. FDA has recently approved two BL/BLI combinations [ceftolozane-tazobactam (trade name: zerbaxa) and ceftazidime-avibactam (trade name: avycaz), respectively], which alleviate the incurable state of drug-resistant bacteria to a large extent. Based on the existing BL and BLI, Chinese pharmaceutical manufactures also have done many researches in the development of BL/BLI combinations. In this paper, we described the progress of the development of antibiotic compounds in China and abroad, the requirements of the regulations on the research and development of drugs, the government's policies for encouraging the development of antibiotics against drug-resistant bacteria, and then analyzed the shortcomings and proposed several suggestions for the R&D of antibiotic compounds, in order to provide references for reasonable development of BL/BLI combination in China.
